While four biosimilars have been approved by the U.S. Food And Drug Administration (FDA) to date, the drug class is still in its infancy.
A biosimilar is an approved drug that it is highly similar to an FDA-approved biologic product, and has no clinically meaningful difference in safety or effectiveness from the original product. Often called copycat drugs, biosimilars offer a cheaper yet comparably effective option to high-priced brand-name drugs. (See also: Amgen Targeting Biosimilars.)
